Browse by author
Lookup NU author(s): Dr Ioana Cosgarea, Dr Thomas Oliphant, Professor Neil RajanORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2024. The treatment of melanoma has witnessed groundbreaking changes over the last decade, transforming the standard of care for patients with high-risk, advanced or metastatic disease. Whilst the treatment approach depends on the stage of disease, the management of primary melanoma remains complete wide excision of the primary. Sentinel node biopsy is offered in selected higher risk melanoma and complete nodal dissection is performed in patients who present with palpable nodal disease. Tumour genetic analysis for BRAF mutation should be performed in all patients with stage IIB to IV disease as this will determine if patients are suitable for targeted treatment with BRAF and MEK inhibitors. Systemic treatment with targeted treatment with BRAF and MEK inhibitors and immunotherapy are recommended as adjuvant treatment options and in metastatic settings. Patients with a personal or family history of three or more melanomas require genetic assessment.
Author(s): Cosgarea I, Oliphant T, Rannan-Eliya S, Rajan N
Publication type: Review
Publication status: Published
Journal: Surgery (Oxford)
Year: 2024
Pages: ePub ahead of Print
Online publication date: 23/10/2024
Acceptance date: 02/04/2018
ISSN (print): 0263-9319
ISSN (electronic): 1878-1764
Publisher: Elsevier Ltd
URL: https://doi.org/10.1016/j.mpsur.2024.09.007
DOI: 10.1016/j.mpsur.2024.09.007
